News for Transgene SA (TRGNF)

Mar 27, 2025 / 05:00PM GMTLucie Larguier - Transgene SA - Chief Financial Officer, Member of the Management Committee Hello everyone. So I'm Lucy, Chief Finance

Debt Conversion: Approximately EUR33 million converted into equity.Majority Shareholder Ownership: TSGH now owns 69% of Transgene.Financial Visibility: Confirm

Sep 24, 2024 / 04:00PM GMTLucie Larguier - Transgene SA - Chief Financial Officer, Member of the Management Committee Thank you, Heidi, and hello, everyone. I h

Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

- Wholly owned programs on track for CTA and/or IND submissions - PBGENE-HBV for Hepatitis B virus in 2024 and PBGENE-PMM for primary mitochondrial myopathy in 2025 - First ARCUS in vivo gene...

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

Legend Biotech's CARVYKTI ® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Mar 27, 2024 / 05:00PM GMTUnidentified Company Representative Thank you, Nadia, and hello, everyone. I'm Lucie. I have the pleasure to introduce you today to Dr

Sep 20, 2023 / 04:00PM GMTOperator Hello, and welcome to the Transgene First Half 2023 Financial Results and Business Update Call. Please note, this conference

May 05, 2023 / 02:00PM GMTOperator Hello, and welcome to the Transgene conference call. My name is Ben, and I will be the coordinator for today's call. Please n

Nov 02, 2022 / 05:00PM GMTOperator Good day, and welcome to the positive interim analysis results of Phase II trial evaluating TG4001 plus avelumab conference c

Sep 07, 2022 / 04:00PM GMTOperator Hello, and welcome to the Transgene First Half 2022 Financial Results and Business Update Call. My name is Courtney, and I'll

Nov 23, 2021 / 01:00PM GMTOperator Welcome to the Transgene Conference Call. Please note this conference is being recorded. (Operator Instructions). I will now

Nov 12, 2020 / 11:00PM GMTOperator Hello, and welcome to the presentation of the Phase Ib/II data of TG4001 plus avelumab in HPV16-positive cancers. My name is

Jul 22, 2020 / 05:15PM GMTOperator Hello, and welcome to the Transgene Reports Results from Clinical Study with TG4001. My name is Monique, and I'll be your coo

RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in...